Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

View Full Paper
Ask AI
Bookmark
Share

Authors

CZChenxuan ZangZLZiyi LiEJElias Jabbour

Discussion

Loading...

Member takes

Overview

Observational analysis reveals RAS pathway mutations increase adverse outcomes in chronic myelomonocytic leukemia, suggesting potential therapeutic strategies.

Key Points

  • EMD-CMML patients showed a median overall survival of 26 months, indicating worse outcomes compared to those without EMD.
  • The study assessed 63 patients with EMD-CMML, identifying a predominance of myeloproliferative variants and RAS pathway mutations.
  • Next generation sequencing revealed substantial RAS pathway activity across EMD sites, particularly in KRAS and PTPN11 mutations.
  • Findings emphasize the need for targeted therapeutic strategies to improve clinical outcomes in these patients.

Cite This Study

Zang et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d841https://doi.org/10.1182/blood-2025-3848
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genomic and transcriptomic signatures of extramedullary multiple myeloma reveal possible drivers of therapeutic resistance2025
  2. 2Single-cell transcriptomics reveals proliferative, immune-evasive, and bone marrow–independent transcriptional programs in extramedullary multiple myeloma.2025
  3. 3Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy2025
  4. 4Beyond the bone marrow: a review of therapeutic approaches for extramedullary disease in multiple myeloma and the significance of MRD assessment.2025 · 2 citations
  5. 5Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma2025